Section 6 of 6
References
196 sources
- Agrawal et al. (2023) (opens in a new tab)
- Agrawal et al. (2026) (opens in a new tab)
- Albert et al. (2023) (opens in a new tab)
- Aqneursa prescribing information (2026) (opens in a new tab)
- Aston et al. (2019) (opens in a new tab)
- Beren Therapeutics ACMG data press release (2026) (opens in a new tab)
- Beren Therapeutics Breakthrough Therapy designation press release (2025) (opens in a new tab)
- Beren Therapeutics CNS data press release (2026) (opens in a new tab)
- Beren Therapeutics financing press release (2026) (opens in a new tab)
- Beren Therapeutics LEMBAZ approval community update (2026) (opens in a new tab)
- Beren Therapeutics LEMBAZ approval press release (2026) (opens in a new tab)
- Beren Therapeutics NDA acceptance press release (2026) (opens in a new tab)
- Beren Therapeutics NDA submission community letter (2025) (opens in a new tab)
- Beren Therapeutics NDA submission press release (2025) (opens in a new tab)
- Beren Therapeutics October 2024 community update (2024) (opens in a new tab)
- Beren Therapeutics October 2025 community update (2025) (opens in a new tab)
- Beren Therapeutics patent estate press release (2026) (opens in a new tab)
- Beren Therapeutics review extension press release (2026) (opens in a new tab)
- Beren Therapeutics September 2024 community update (2024) (opens in a new tab)
- Beren Therapeutics test for NPC press release (2026) (opens in a new tab)
- Beren Therapeutics webinar community update (2026) (opens in a new tab)
- Berry-Kravis et al. (2018) (opens in a new tab)
- Berry-Kravis et al. (2025) (opens in a new tab)
- Berry-Kravis et al. (2026a) (opens in a new tab)
- Berry-Kravis et al. (2026b) (opens in a new tab)
- Berry-Kravis et al. (2026c) (opens in a new tab)
- Berry-Kravis et al. (2026d) (opens in a new tab)
- Berry-Kravis et al. (2026e) (opens in a new tab)
- Berry-Kravis et al. (2026f) (opens in a new tab)
- Berry-Kravis et al. (2026g) (opens in a new tab)
- Bianconi et al. (2019) (opens in a new tab)
- Bolton et al. (2022) (opens in a new tab)
- Bonney et al. (2010) (opens in a new tab)
- Bountouvi et al. (2021) (opens in a new tab)
- Breen et al. (2013) (opens in a new tab)
- Bremova-Ertl and Patterson (2025) (opens in a new tab)
- Bremova-Ertl et al. (2022) (opens in a new tab)
- Bremova-Ertl et al. (2024) (opens in a new tab)
- Burchard et al. (2026a) (opens in a new tab)
- Burchard et al. (2026b) (opens in a new tab)
- Burton et al. (2021) (opens in a new tab)
- California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026) (opens in a new tab)
- California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026) (opens in a new tab)
- Cawley et al. (2025) (opens in a new tab)
- ClinicalTrials.gov NCT00344331 (opens in a new tab)
- ClinicalTrials.gov NCT01747135 (opens in a new tab)
- ClinicalTrials.gov NCT02534844 (opens in a new tab)
- ClinicalTrials.gov NCT02534844 API record (opens in a new tab)
- ClinicalTrials.gov NCT02534844 results (opens in a new tab)
- ClinicalTrials.gov NCT03643562 (opens in a new tab)
- ClinicalTrials.gov NCT03643562 API record (opens in a new tab)
- ClinicalTrials.gov NCT03643562 results (opens in a new tab)
- ClinicalTrials.gov NCT03879655 (opens in a new tab)
- ClinicalTrials.gov NCT03879655 results (opens in a new tab)
- ClinicalTrials.gov NCT04860960 (opens in a new tab)
- ClinicalTrials.gov NCT04958642 (opens in a new tab)
- ClinicalTrials.gov NCT04958642 results (opens in a new tab)
- ClinicalTrials.gov NCT05368038 (opens in a new tab)
- ClinicalTrials.gov NCT07054515 (opens in a new tab)
- CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
- Crumling et al. (2017) (opens in a new tab)
- Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
- Diaz et al. (2022) (opens in a new tab)
- Drugs.com Lembaz FDA approval history (2026) (opens in a new tab)
- Drugs@FDA NDA 219132 (opens in a new tab)
- Drugs@FDA NDA 220996 (opens in a new tab)
- EMA orphan designation EU/3/13/1124 (2013) (opens in a new tab)
- Erickson and Fiorenza (2017) (opens in a new tab)
- European Medicines Agency Aqneursa EPAR (2026) (opens in a new tab)
- European Medicines Agency Meplyffa refusal (2026) (opens in a new tab)
- European Medicines Agency Meplyffa refusal questions and answers (2026) (opens in a new tab)
- European Medicines Agency Zavesca product information (2026) (opens in a new tab)
- Evans et al. (2021) (opens in a new tab)
- Farhat et al. (2022) (opens in a new tab)
- Farmer et al. (2019) (opens in a new tab)
- Farmer et al. (2026) (opens in a new tab)
- FDA (2024) (opens in a new tab)
- FDA Lembaz approval press announcement (2026) (opens in a new tab)
- FDA Miplyffa approval announcement (2024) (opens in a new tab)
- FDA NDA 220996 approval letter (2026) (opens in a new tab)
- FDA NDA approval letter (2024) (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2013) (opens in a new tab)
- Fierce Pharma LEMBAZ approval report (2026) (opens in a new tab)
- Fierce Pharma phase 3 results report (2026) (opens in a new tab)
- Freihuber et al. (2023) (opens in a new tab)
- Garver et al. (2007) (opens in a new tab)
- Gascón-Bayarri et al. (2022) (opens in a new tab)
- GeneDx Zevra NPC sponsored genetic testing program press release (2026) (opens in a new tab)
- Golden et al. (2023) (opens in a new tab)
- Gutić et al. (2022) (opens in a new tab)
- Hastings et al. (2019) (opens in a new tab)
- Héron et al. (2012) (opens in a new tab)
- Hiwot et al. (2026) (opens in a new tab)
- ICER Launch Price and Access Report (2026) (opens in a new tab)
- Imrie et al. (2009) (opens in a new tab)
- Jiang et al. (2014) (opens in a new tab)
- Jiang et al. (2016) (opens in a new tab)
- Jiang et al. (2019) (opens in a new tab)
- Jiao et al. (2026) (opens in a new tab)
- Julich et al. (2026) (opens in a new tab)
- Kao et al. (2020) (opens in a new tab)
- King et al. (2014) (opens in a new tab)
- Koens et al. (2016) (opens in a new tab)
- Labrecque et al. (2021) (opens in a new tab)
- LEMBAZ billing and coding guide (2026) (opens in a new tab)
- LEMBAZ caregiver website (2026) (opens in a new tab)
- LEMBAZ dosing and administration guide (2026) (opens in a new tab)
- LEMBAZ Family Support terms and conditions (2026) (opens in a new tab)
- LEMBAZ letter of medical necessity template (2026) (opens in a new tab)
- LEMBAZ patient enrollment form (2026) (opens in a new tab)
- Lembaz prescribing information (2026) (opens in a new tab)
- LEMBAZ prior authorization checklist (2026) (opens in a new tab)
- Maarup et al. (2015) (opens in a new tab)
- Mallinckrodt Form 10-K (2019) (opens in a new tab)
- Mallinckrodt Form 10-K (2020) (opens in a new tab)
- Mallinckrodt plan of reorganization exhibit (2021) (opens in a new tab)
- Mallinckrodt VTS-270-001 protocol (2021) (opens in a new tab)
- Mandos December 2021 community update (2021) (opens in a new tab)
- Mandos expanded access program continuation letter (2021) (opens in a new tab)
- Mandos Health survival and biomarker analyses press release (2025) (opens in a new tab)
- Mandos May 2022 community update (2022) (opens in a new tab)
- Mandos November 2022 community update (2022) (opens in a new tab)
- Matsuo et al. (2014) (opens in a new tab)
- Matsuo et al. (2024) (opens in a new tab)
- Medicaid.gov State Drug Utilization Data 2025 (2026) (opens in a new tab)
- Medicaid.gov State Drug Utilization Data 2025 for MIPLYFFA (2026) (opens in a new tab)
- Medicaid.gov State Drug Utilization Data 2026 (2026) (opens in a new tab)
- Medicaid.gov State Drug Utilization Data 2026 for MIPLYFFA (2026) (opens in a new tab)
- Medscape adrabetadex drug monograph (2026) (opens in a new tab)
- Mengel et al. (2020) (opens in a new tab)
- Mengel et al. (2021a) (opens in a new tab)
- Mengel et al. (2021b) (opens in a new tab)
- Mengel et al. (2025a) (opens in a new tab)
- Mengel et al. (2025b) (opens in a new tab)
- Mengel et al. (2026) (opens in a new tab)
- Miplyffa prescribing information (2024) (opens in a new tab)
- Modin et al. (2021) (opens in a new tab)
- Nafees et al. (2026) (opens in a new tab)
- New York State Medicaid eMedNY (opens in a new tab)
- New York State Medicaid list of reimbursable drugs (2026) (opens in a new tab)
- NHS England Specialised Services Quality Dashboard lysosomal storage disorders metric definitions (2022) (opens in a new tab)
- NICE arimoclomol appraisal (2022) (opens in a new tab)
- NICE VTS-270 appraisal (2026) (opens in a new tab)
- NICHD phase 1-2a trial news release (2017) (opens in a new tab)
- Oklahoma Health Care Authority Drug Utilization Review Board packet (2025) (opens in a new tab)
- Ontario Exceptional Access Program Zavesca reimbursement guidelines (2011) (opens in a new tab)
- Oregon State University Drug Use Research and Management Program (2025) (opens in a new tab)
- Orphazyme complete response letter announcement (2021) (opens in a new tab)
- Ory et al. (2017) (opens in a new tab)
- Ottinger et al. (2014) (opens in a new tab)
- Padilla et al. (2025) (opens in a new tab)
- Patterson et al. (2007) (opens in a new tab)
- Patterson et al. (2010) (opens in a new tab)
- Patterson et al. (2015) (opens in a new tab)
- Patterson et al. (2020a) (opens in a new tab)
- Patterson et al. (2020b) (opens in a new tab)
- Patterson et al. (2021) (opens in a new tab)
- Patterson et al. (2025) (opens in a new tab)
- Pharmaphorum LEMBAZ approval report (2026) (opens in a new tab)
- Pineda et al. (2016) (opens in a new tab)
- Porter et al. (2025) (opens in a new tab)
- Porter et al. (2026) (opens in a new tab)
- Rafael Holdings Form 10-K (2026) (opens in a new tab)
- Rafael Holdings investor presentation (2026) (opens in a new tab)
- Rafael Holdings TransportNPC topline results release (2026) (opens in a new tab)
- Roch Santed et al. (2017) (opens in a new tab)
- Rodriguez-Gil et al. (2025) (opens in a new tab)
- Scottish Medicines Consortium (2010) (opens in a new tab)
- Sharma et al. (2023) (opens in a new tab)
- Sharma et al. (2026) (opens in a new tab)
- Sidhu et al. (2020) (opens in a new tab)
- Solomon et al. (2020) (opens in a new tab)
- Solomon et al. (2026) (opens in a new tab)
- Sucampo Vtesse acquisition press release (2017) (opens in a new tab)
- Tchan et al. (2026) (opens in a new tab)
- Texas Department of State Health Services 2025 Annual WAC Report (2026) (opens in a new tab)
- Texas Department of State Health Services 2026 Annual WAC Report (2026) (opens in a new tab)
- Texas Department of State Health Services Prescription Drug Price Disclosure Program data overview (opens in a new tab)
- van Karnebeek et al. (2015) (opens in a new tab)
- Vanier (2010) (opens in a new tab)
- Vite et al. (2015) (opens in a new tab)
- Vtesse Breakthrough Therapy designation press release (2016) (opens in a new tab)
- Vtesse VTS-270-302 protocol (2021) (opens in a new tab)
- Vtesse VTS301 protocol amendment 15 (2021) (opens in a new tab)
- Vtesse VTS301 protocol synopsis (2019) (opens in a new tab)
- Vtesse VTS301 statistical analysis plan (2018) (opens in a new tab)
- Walterfang et al. (2012) (opens in a new tab)
- Wassif et al. (2016) (opens in a new tab)
- Wraith et al. (2010) (opens in a new tab)
- Yanjanin et al. (2010) (opens in a new tab)
- Yergey et al. (2017) (opens in a new tab)
- YODA Project data request 2021-4741 (opens in a new tab)
- ZAVESCA prescribing information (2020) (opens in a new tab)
- Zevra Therapeutics advisory committee release (2024) (opens in a new tab)
- Zevra Therapeutics Form 10-K (2026) (opens in a new tab)
- Zevra Therapeutics third quarter 2026 results release (2026) (opens in a new tab)